Cite
HARVARD Citation
Ay, S. et al. (2022). FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. Journal of chemotherapy. pp. 465-471. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ay, S. et al. (2022). FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. Journal of chemotherapy. pp. 465-471. [Online].